HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

In this episode of HOPA Now, Dr. Kirollos Hanna highlights the fundamentals regarding multiple myeloma, the 14th most common cancer in the U.S. He offers details regarding diagnosis data and risk factors, the pathophysiology and molecular biology of multiple myeloma, the tools used to stage select patients and the importance of patient adherence to varying degrees of therapy regimens.

In this episode you will learn:

Multiple Myeloma: Fundamentals

Diagnosis data and figures surrounding multiple myeloma
Risk factors for developing multiple myeloma
The main differentiating factors for MGUS smoldering and active myeloma
Pathophysiology and disease-related symptoms of multiple myeloma
C.R.A.B. symptoms, their causes, and common resulting effects
Molecular biology of myeloma and cytogenetic abnormality prognostic factors
High-risk differentiating factors and the tools used to stage select patients
The importance of patient adherence to therapy regimens

Mentioned in This Episode:

HOPA

Quotes:

“We know that cytogenetic abnormalities oftentimes have a lot to do with preventing normal differentiation of apoptosis.” — Dr. Kirollos Hanna

“It is very rare or uncommon to see patients have IGM or IGD myeloma, and extremely rare to see patients not have any M proteins present in the blood or the urine.” — Dr. Kirollos Hanna

“Response criteria ranges anywhere from stringent and complete response all the way to progressive or refractory disease.” — Dr. Kirollos Hanna

[Education] Multiple Myeloma: Fundamentals